Ligandrol 4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It's in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of tolerability and patient acceptance due to tissue-selective mechanism of action and an route of administration.
